ACCESS Newswire

Capital.com

Share
Markets are in the doldrums but retail investors are raring to go: Capital.com survey

UK retail investors are bullish on equities but worry about the cost-of-living crisis, falling stock prices and geopolitical risks in the year ahead.

LONDON, UK / ACCESSWIRE / January 26, 2024 / Seven in 10 retail (77%) traders and investors in the UK are taking a neutral-to-optimistic view on financial markets in 2024, according to a new nationally representative survey commissioned by online retail trading platform, Capital.com- with 35% of respondents expecting stocks to be the best performing asset class over the next six to 12 months. These findings affirm that market confidence among UK investors remains high, despite wider macro risks.

The findings are based on a nationally representative survey of 19,451 UK adults, of which 2,036 are traders or investors. In this survey, investors and traders are defined as adults who had invested or traded in mutual funds, bonds, forex, commodities, options, CFDs or spread bets in the past 12 months. The survey, commissioned by Capital.com and polled by Find Out Now, was carried out between 21 Nov to 4 Dec 2023.

Commenting on the upbeat investor sentiment revealed by the findings of the survey, Daniela Hathorn, Senior Market Analyst, Capital.com, said:

"Supported by positive economic data at the tail end of 2023, investors are perhaps approaching 2024 with an air of optimism. Yes, there are pockets of weakness in the economy, especially in the UK and the euro area, but global economic growth in 2023 has fared much better than expected. Of course that doesn't mean the same will happen in 2024, but with investors widely expecting interest rates to fall this year, many expect the recent resilience to be carried through as looser financing conditions make up for some of the loss in productivity and growth."

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

The survey further revealed a healthy interest in equity markets, with 35% of respondents expecting stocks to do well in 2024 followed by gold (32%) and oil & gas (31%). Positive market sentiment was further reflected in investors' capital allocation decisions with 30% of respondents saying they would buy or trade stocks in the next six to 12 months -with the majority focusing on growth and tech stocks (52%). Just 9% said they would move their capital into cash over the same period.

According to Daniela, investors' preference for stocks over other asset classes in 2024 is likely the result of improving market conditions.

"Stocks are typically favoured by investors because they are considered the ‘most tangible' of all non-physical investments, which simply means they are easier to measure and understand than other asset classes. Add to that expectations for rate cuts in 2024 and you have the ideal impetus for equity market enthusiasts. With the potential for lower interest rates in 2024, investors are perhaps expecting company valuations to improve making them attractive investments. Tech stocks are renowned for being the market sweethearts as they tend to hold their value even in difficult times, while offering investors greater returns. Similarly, growth stocks can benefit from improved market sentiment and higher valuations."

Cost-of-living crisis results in greater awareness of saving & investing activities

Despite the market optimism, respondents cited the ongoing cost-of-living crisis as the biggest risk to their investment and trading returns with 22% of those surveyed saying they would need to free up investment capital to cover higher expenses.

Consumers have less money to play with, putting pressure on many to amend their trading, savings and investment habits. When asked what they would do with an extra £10,000, the majority of respondents (57%) said they would either put it into a savings account or trade or invest it. Just 10% said they would spend it while 14% said they would overpay their mortgage or put it into a pension plan (6%).

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

"The recent period of high inflation has led to a general devaluation of capital unless it was invested in an asset that provided higher returns. It is not surprising that people are more conscious about how they manage their money now that they have seen the cost of living increase exponentially -it is no longer enough to simply save, consumers want to make up for the loss in their purchasing power. This has led to more awareness about investing, leading many to increase their capital allocations to return-generating activities rather than spending," said Daniela.

Other concerns for UK traders and investors in 2024 include falling stock prices (20%) , geopolitical risk (18%) and recession (16%). Tellingly, only 9% said that higher interest rates were of concern to them, suggesting investors expect the UK economy to improve in the year ahead.

"Markets are currently pricing in between five to six 25 bps rate cuts in 2024 from the BoE. Meanwhile, the central bank itself is expecting to make around three rate cuts this year. These misaligned expectations could drive momentum in UK assets over the coming months, especially as upcoming economic data reveals which set of expectations appear to be correct. Nonetheless, rate cuts are expected so investors may be looking to get higher yields on bonds while they can," she added.

END

Notes to Editors

About Capital.com

Capital.com is a high-growth fintech company empowering people to participate in financial markets through simple and innovative online trading platforms. Its intuitive award-winning platform, available on web and app, enables investors to trade thousands of world-renowned markets. To help investors trade with confidence, the platform is fitted with robust risk management controls and transparent pricing while its all-in-one ‘Investmate' app delivers financial lessons and educational content to support clients in their investment journey. Capital.com has a global network with offices located in Cyprus, UK and Australia.

Capital Com (UK) Limited is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 793714. Capital Com SV Investments Limited is Authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC), under licence number 319/17. Capital Com Australia Pty Ltd is authorised and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL Number 513393.

To find out more, please visit: www.capital.com

Disclosures

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. Professional clients can lose more than they deposit. All trading involves risk. Please refer to our Risk Disclosure Statement.

Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.

The value of shares and ETFs bought through a share dealing account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.

Capital Com (UK) Limited ("CCUK") is registered in England and Wales with company registration number 10506220. CCUK is authorised and regulated by the Financial Conduct Authority ("FCA"), under registration number 793714."

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as "investment research" has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.

Shamillia Sivathambu
+44 79000 16469
shamillia.sivathambu@capital.com

SOURCE: Capital.com



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

SK tes Launches New Circular IT Facility in Shannon, Expanding Ireland’s Role in Global Sustainable Tech Services24.4.2025 09:30:00 CEST | Press release

SHANNON, IE / ACCESS Newswire / April 24, 2025 / SK tes, a global leader in sustainable IT asset disposition (ITAD) and technology lifecycle services, has announced plans to open a new 36,000 square foot purpose-built facility in Shannon, marking a major vote of confidence in Ireland's thriving data and technology sector. The new facility will deliver comprehensive ITAD, data center decommissioning, and technology lifecycle management services to some of Ireland's largest enterprises, including hyperscale data center operators, while supporting national sustainability and circular economy goals. It will also create over 25 skilled jobs in one of the country's fastest-growing tech regions. "Ireland is at the forefront of Europe's digital economy, and our investment in Shannon reinforces our commitment to helping Irish companies manage technology securely, sustainably, and at scale," said Eric Ingebretsen, Chief Commercial Officer at SK tes. "This facility will allow us to meet the uniqu

Sauce Labs Launches Industry-First Enterprise Scale iOS 18 Testing on Sauce Labs Virtual Device Cloud, Boosting Test Speeds up to 40%24.4.2025 08:00:00 CEST | Press release

Leading test automation platform, powering development for over 300,000 active users and having executed more than 8 billion tests, enables developers and QA teams to ensure app quality on Apple's latest OS with unprecedented performance and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2025 / Sauce Labs Inc., the leading platform for continuous quality, trusted by dev teams around the world to deliver apps users love, today announced the general availability of iOS 18 testing on its Virtual Device Cloud (VDC). Leveraging its new, high-performance Apple Silicon cloud infrastructure, Sauce Labs offers the market's most scalable enterprise-ready solution for automated mobile app and web testing on iOS 17.5, iOS 18, and beyond, enabling teams to execute tests up to 40% faster compared to previous versions. This launch addresses the critical need for timely testing support driven by Apple's transition to its proprietary Apple Silicon architecture and the rapid adoption rate of new

Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection24.4.2025 07:00:00 CEST | Press release

Delivering Effective Germ Control in Five Minutes BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.* NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential. "We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patie

TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release

LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea

BioNxt Solutions Prepares for Human Bioequivalence Study For MS23.4.2025 03:05:00 CEST | Press release

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish. T

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye